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Abstract
Purpose: To investigate the biological function of HOXB5 in human bladder cancer and explore whether the HOXB5 39-UTR
SNP (1010A/G), which is located within the microRNA-7 binding site, was correlated with clinical features of bladder cancer.
Methods: Expression of HOXB5 in 35 human bladder cancer tissues and 8 cell lines were examined using real-time PCR and
immunohistochemistry. Next, we explored the biological function of HOXB5 in vitro using cell proliferation, migration and
colony formation assays. Using bioinformatics, a SNP (1010A/G) was found located within the microRNA-7 binding site in
the 39-UTR of HOXB5. Real-time PCR was used to test HOXB5 expression affected by different alleles. Finally, multivariate
logistic regression analysis was used to determine the relationship between SNP (1010A/G) frequency and clinical features in
391 cases.
Results: HOXB5 was frequently over-expressed both in bladder cancer tissues and cell lines. Inhibition of HOXB5 suppressed
the oncogenic function of cancer cells. Next, we demonstrated that a SNP (1010A/G), located within the microRNA-7
binding site in the 39-UTR of HOXB5, could affect HOXB5 expression in bladder cancer mainly by differential binding activity
of microRNA-7 and SNP-related mRNA stability. Finally, we also showed the frequency of 1010G genotype was higher in
cancer group compared to normal controls and correlated with the risk of high grade and high stage.
Conclusion: HOXB5 is overexpressed in bladder cancer. A miRNA-binding SNP (1010A/G) located within 39-UTR of HOXB5 is
associated with gene expression and may be a promising prognostic factor for bladder cancer.
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Introduction
Urinary bladder cancer is the most common urological tumor in
China [1]; however, the mechanisms of bladder cancer tumori-
genesis have not been well illustrated. Data show that most of the
bladder cancers are induced by carcinogens that damage the
DNA. The sensitivity of the transitional epithelium’s microenvi-
ronment may be another important factor during tumorigenesis
[2]. Oncogenes and tumor suppressors have also been reported to
play important roles in bladder cancer [3]. Recently, genetic
changes including SNPs, deletions, insertions, and changes of
DNA copy number have been found to be involved in bladder
carcinogenesis.
A homeobox (HOX) is a sequence of about 180 nucleotides
within genes that code for a protein domain called home-
odomain. Studies showed that HOX genes constitute as much as
0.1–0.2% of the whole vertebrate genome [4]. HOX genes are
highly conserved across vast evolutionary distances and encode
nuclear proteins that act as transcription factors (TF) during
normal organ development [5]. In recent years, the HOX gene
family has also been associated with human diseases especially
cancers. For instance, loss of HOXA5 in breast cancer [6], over-
expression of HOXA10 in acute myeloid leukemia (AML) [7],
gene mutations of HOXD4 in renal and colon cancer [8] and
overexpression of HOXC4 in human bladder cancer [9] have
been reported. HOXB5 (NM_002147.3), located on human
chromosome 17, is a member of the HOX gene family that is
involved in normal lung and gut development in mouse and
human [10]. HOXB5 has been reported to be related to human
diseases including AML [11], congenital cystic adenomatoid
malformation (CCAM) [12] and bronchopulmonary sequestra-
tion (BPS) [13]. Also, the HOXB5 gene was found to be highly
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important potential targets in the treatment of ovarian cancer
[14]. The biological function of HOXB5 in urological carcino-
mas have not been reported. In a pilot study, we found that
HOXB5 was frequently over-expressed in human bladder cancer
tissues and cell lines, suggesting that it may be a candidate
oncogene in bladder cancer.
In the past ten years, the involvement of microRNAs (miRNAs)
in human cancers has been widely studied. MiRNAs repress the
expression of the target mRNA by binding to the 39 untranslated
region (3’-UTR) of the mRNA. In human bladder cancer,
miRNAs had been shown to be important factors during
tumorigenesis. In a previous study, we reported that miRNA-
143 and miRNA-125b acted as tumor suppressors in human
bladder cancer [15,16]. In another study it was reported that miR-
7 was down-regulated in bladder cancer and may suppress tumor
growth by inhibiting growth factor receptor expression and by
impairing the anti-apoptotic Akt pathway [17].
Single-nucleotide polymorphisms (SNPs), the most common
form of genetic variations in the human genome, contribute to
different human phenotypes. SNPs have been associated with
many human diseases, especially cancers. In recent years, SNPs
located within the miRNA-binding site of a miRNA target (also
called miRNA-binding SNP) have been found to be important
during tumorigenesis. In a previous study, our group suggested
that SNP (1805C/T) in the miR-181a binding site of the Mel-18
gene was related to some clinical features of prostate cancer [18].
In a pilot study, we found a possible miRNA-binding SNP
(1010A/G) in the 39-UTR of the HOXB5 gene using the NCBI
SNP database (http://www.ncbi.nlm.nih.gov/snp/) and miRbase
(http://www.mirbase.org/).
In this study, we showed that the HOXB5 gene was over-
expressed and acted as an oncogene in human bladder cancer. We
also found a SNP (1010 A/G) in the 39-UTR of the HOXB5 gene
which is within the miRNA-7 binding site. We have shown that
this SNP could affect the expression of HOXB5 mainly by
interfering with the function of miRNA-7 and SNP-related mRNA
stability; Furthermore, the frequency of 1010G genotype was
higher in cancer group compared to normal controls, and was
found to be correlated with the risk of high grade and high stage.
To our knowledge, this is the first study of the involvement of
polymorphisms in the miRNA binding site of HOXB5 in human
bladder cancer.
Materials and Methods
Patients and Tissues
391 bladder cancer patients were enrolled in our study. This
study was approved by the Institute Research Ethics, Sun Yat-
sen University, China. Informed consent was written and
obtained from all the subjects in our study. All the patients
had primary bladder cancers; no previous treatment had been
conducted before the operation. The cancer samples were
obtained from patients who underwent resection of bladder
cancer. The samples were collected between 2007 and 2010 at
the Department of Urology, Sun Yat-sen Memorial Hospital,
Sun Yat-sen University, Guangzhou, China and Department of
Urology, Southwest Hospital, Chongqing, China. All bladder
specimens were immediately snap frozen in liquid nitrogen and
stored at 280uC. Histology of the tissues was independently
evaluated by two pathologists, and the clinical stage of bladder
cancer was determined using the 2002 tumor-node-metastasis
(TNM) classification system.
Cell Lines and Cell Culture
Cell lines used in our study were obtained from American
Tissue Type Culture Collection (ATCC, Manassas, VA, USA);
they include T24, 5637, TCCSUP, HT-1376, UM-UC-3, J82,
RT4, EJ and the SV40-transformed kidney cell line 293T. The
cells were cultured in a humidified air atmosphere of 5% CO2 at
37uC, and all media were supplemented with 10% fetal bovine
serum (Hyclone, Logan, UT, USA). T24 was cultured in McCoy’s
5a medium (modified); 5637 was cultured in RPMI 1640 medium;
J82, UM-UC-3, TCCSUP and HT-1376 were cultured in Eagle’s
minimum essential medium (EMEM) (Hyclone); and RT4, EJ and
SV40-transformed kidney cell line 293T were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) (Hyclone).
RNA Extraction and Quantitative Real-time PCR
Total RNA was extracted from the patients’ bladder samples
or cell lines using TRIzol reagent (Invitrogen, Carlsbad,
California, USA) according to the manufacturer’s protocol.
Quantitative real-time PCR (qPCR) was done using the SYBR
green assay (TaKaRa Biotechnology, Dalian, China) on a Roche
LightCycler 480 machine (Roche Applied Science, Mannheim,
Germany). qPCR was performed as followed: an initial
predenaturation step for 30 seconds at 95uC, followed by
amplification of 40 cycles at 95uC for 5 seconds and at 60uC
for 20 seconds, melting curve analysis was performed at the end.
All reactions were done in a 20 mL reaction volume in triplicate.
The expression level of HOXB5 was evaluated using the
comparative Ct method. GAPDH was used as an internal
control. The primers used for HOXB5 were: sense, 59-
TGAAGCACAGGGTTATAACGACCA-39, antisense, 59-
GCAGCGGGATCCCTGTAAGA-39; and for GAPDH the
primers were: sense, 59- GAAGGTGAAGGTCGGAGTC-39,
antisense, 59- GAAGATGGTGATGGGATTTC-39.
Immunohistochemistry
Paraffin-embedded, formalin-fixed tissues were cut into 5-mm
section, placed on a polylysine-coated slide, deparaffinized in
xylene, rehydrated using graded ethanol, quenched for endoge-
nous peroxidase activity in 0.3% hydrogen peroxide and processed
for antigen retrieval by microwave heating in 10 mM citrate buffer
(pH 6.0). Sections were incubated at 4uC overnight with HOXB5
rabbit polyclonal antibody (1:100, AbCam, Cambridge, MA,
USA). Immunostaining was performed using the ChemMate
TM
DAKO EnVision
TM Detection Kit (DakoCytomation, Glostrup,
Denmark), which resulted in a brown precipitate at the antigen
site. Subsequently, sections were counterstained with hematoxylin
(Zymed Laboratories, South San Francisco, CA, USA) and
mounted in nonaqueous mounting medium. The primary
antibody was omitted for the negative controls.
Western Blot
Protein was extracted from bladder cancer tissues and cell lines
as described [19]. Briefly, 30 mg of protein from each sample was
separated by electrophoresis in a sodium dodecyl sulfate poly-
acrylamide gel before being transferred to polyvinylidene fluoride
membranes (Millipore, Billerica, MA, USA) for 2 hours. Then
the membranes were blocked for 1 hour at room temperature
using 5% bovine serum albumin (BSA), and incubated in TBST
(Tris buffered saline with 0.05% tween) containing rabbit
polyclonal IgG2a anti-HOXB5 (1:1000, AbCam) or GAPDH
(1:1000, Cell Signaling Technology, Beverly, MA, USA) over-
night at 4uC. The membranes were incubated with peroxidase-
conjugated goat anti-rabbit immunoglobulin (1:5000, Cell
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using a commercial ECL kit (Pierce, Rockford, IL, USA).
Cell Transfection with si-HOXB5 and miRNA-7
siRNAs designed to HOXB5 and miRNA-7 mimics were
transfected into the bladder cancer cells T24, 5637 and TCCSUP
using Lipofectamine-RNAiMAX (Invitrogen). The sequences used
for si-HOXB5 were, sense: 59-GGAUGGACCUCAGCGU-
CAATT-39, antisense: 59-UUGACGCUGAGGUCCAUCCTT-
39; for miR-7 mimics, sense: 59-CAACAAAUCACAGUCUGC-
CAUA-39, antisense: 59-UAUGGCAGACUGUGAUUUGUUG-
39; and for the negative control, sense: 59-UUCUCCGAACGU-
GUCACGUTT-39, antisense: 59-ACGUGACACGUUCGGA-
GAATT-39. All the RNA oligoribonucleotides were purchased
from Genepharma (Shanghai, China). One day before trans-
fection, 2610
5 cells were seeded onto a six-well plate. The next
day, when the cells reached 70–80% confluence, they were
transfected with RNA at a final concentration of 100 nM
according to Lipofectamine-RNAiMAX’s protocol. The trans-
fection efficiency measured by qPCR, was 70% for T24, 72% for
5637 and 75% for TCCSUP (data not shown).
Cell Proliferation Assay
Human bladder cancer cell lines T24, 5637 and TCCSUP were
plated onto 6-well plates and incubated at 37uC in a 5% CO2
incubator one day before transfection. After transfection with
siRNAs (100 nM) or a negative control for 24 hours, the cells were
collected and plated onto 96-well plates for cell viability evaluation
using a CCK8 assay (Cell Counting Kit-8) (Dojindo Laboratories,
Japan) according to the protocol [20].
In vitro Cell Migration Assay
After the bladder cancer cell lines T24, 5637 and TCCSUP
were transfected with si-HOXB5 (100 nM) or nonspecific control
(NC) siRNA for 24 hours, the cells were harvested and
suspended in 100 mL serum-free medium and then plated
(1610
4 cells) in the upper compartment of Transwell plates
(Corning, NY, USA). The Transwell inserts were then placed
into the lower compartment of a 24-well plate containing 600 mL
of the medium with 20% FBS as the chemo-attractant. After a 24
hour incubation period, the cells remaining on the top surface of
the membrane were removed and the cells on the lower surface
were fixed in 100% methanol for 30 minutes, followed by
staining with 0.1% crystal violet solution for 30 minutes. Cells
that stained purple were defined as positive and the images were
captured using a microscope (106) (Olympus, Center Valley, PA,
USA).
Colony Formation Assay
After transfection with si-HOXB5 (100 nM) or NC siRNA for
24 hours, the human bladder cancer cells T24, 5637 and
TCCSUP were collected and placed onto a fresh six-well plate
(500 cells for T24, and 1,000 cells for 5637 and TCCSUP). The
cells were cultured for about 2 weeks to form colonies. Colonies
were fixed with 100% methanol and stained with 0.1% crystal
violet in 20% methanol for 15 min. Colony-forming efficiency was
calculated as colonies/plated cells 6100%.
Bioinformatics
The NCBI SNP database (http://www.ncbi.nlm.nih.gov/snp/)
was used to find SNPs located within the 39-UTR of the HOXB5
gene. Four publicly available algorithms, PicTar (http://pictar.
mdc-berlin.de/), TargetScan (http://www.targetscan.org/), mi-
Randa (http://www.microrna.org/) and DIANA microT (http://
diana.pcbi.upenn.edu/) were used to predict which of the human
miRNAs in miRbase (http://www.mirbase.org/) may bind to the
39-UTR of HOXB5. The miRNAs that were predicted by at least
2 of the algorithms to bind were accepted as candidates for further
study. The mRNA secondary structure prediction tool MFOLD
(http://mfold.rna.albany.edu/) was used to predict the secondary
structure of the HOXB5 mRNA. Small minimal free energy
(MFE) indicates high stability of the predicted mRNA secondary
structure.
Luciferase Reporter Assay
We construct luciferase reporter plasmids with the HOXB5 39-
UTR fragment that contained the putative binding sites for the
candidate miRNA and subcloned them into the psiCHECK-2
Vector (Promega, Madison, WI, USA) to produce the psi-
CHECK-2-39-UTR-WT plasmid. The mutant HOXB5 39-UTR
was generated using the fusion PCR method and then it also
subcloned into the psiCHECK-2 Vector to produce the
psiCHECK-2-39-UTR-MUT plasmid. DNA sequencing analysis
was used to confirm the sequence of the constructed plasmids.
For the luciferase reporter assay, HEK-293T cells (2610
4) were
placed onto a 24-well plate one day before transfection. The next
day 0.5 mg of either the psiCHECK-2-39-UTR-WT or the
psiCHECK-2-39-UTR-MUT, and either the miRNA or the
negative control were cotransfected into the HEK-293T cells
using Lipofectamine2000 (Invitrogen). Assays were performed 48
hours after transfection using the Dual-Luciferase Reporter Assay
System (Promega). Luciferase activity was detected using the
GloMax-Multi Detection System (Promega). The Renilla lucifer-
ase signals were normalized to the internal firefly luciferase
transfection control. Transfections were done in triplicate in
independent experiments.
DNA Extraction and HOXB5 Genotyping Analysis
Total DNA was extracted from the patients’ bladder cancer
samples and cell lines using QIAamp reagent (QIAGEN,
Germantown, MD, USA) according to the manufacturer’s pro-
tocol. HOXB5 genotyping was performed using a DNA sequenc-
ing assay. A 334 bp DNA fragment containing the SNP in the 39-
UTR of HOXB5 gene was amplified from genomic DNA. The
PCR primers used were, forward 59-GCGCATGAAGTGGAA-
GAAGG-39, reverse 59-TTGGGACAAGCAGAAGGGAG-39.
The amplified DNA fragment was sequenced using GENESCAN
software (Applied Biosystems, Foster City, CA, USA).
Measurement of the Expression of HOXB5 mRNA
The HOXB5 mRNA level was measured in 3 bladder cancer
cell lines (5637, J82 and RT4) and 13 bladder cancer tissues.
Region-specific Taqman probes were designed to detect the SNP
in the 39-UTR of the HOXB5 mRNA. The cDNA from the cell
lines and cancer tissues were subjected to qPCR and the
fluorescence (VIC for 1010A, FAM for 1010G) was measured
using LightCycler 480 Probes Master (Roche Applied Science,
Mannheim, Germany).
Genomic DNA was also extracted from cell lines and cancer
tissues as mentioned. As an internal control, qPCR was performed
to determine the genomic DNA levels of HOXB5 using the same
region-specific Taqman probes.
HOXB5 mRNA Half-life
qPCR was also used to measure the half-life of the HOXB5
mRNA. 1610
6 T24 and TCCSUP bladder cancer cells were
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ml), which inhibits genetic transcription, was added to the cells.
After treated with actinomycin D, the cells were lysed using
TRIzol at different time points, 0 h, 4 h, 8 h, 12 h, 24 h and
48 h. Total RNA was extracted and the HOXB5 mRNA level
was quantified by qPCR using the Taqman assay as previously
described above.
Figure 1. HOXB5 is over-expressed in human bladder tumors. A. Expression of HOXB5 in 35 bladder cancer tissues relative to normal adjacent
tissues (NAT). Columns above the X-axis indicate overexpression of HOXB5; those below the X-axis indicate down-expression of HOXB5 relative to
NAT. B. Expression of HOXB5 in eight bladder cancer cell lines relative to normal bladder cells. Columns above the X-axis indicate overexpression of
HOXB5; those below the X-axis indicate down-expression of HOXB5 relative to normal cells. Fold changes .1 was considered to be positive.
C. HOXB5 expression in primary transitional cell bladder cancer tissues detected by immunohistochemistry. C1 and C2, Bladder cancer tissues, G2
grade. C3, Bladder cancer tissue, G3 grade. C4, Normal bladder tissue. All images are 6100. Staining: brown, HOXB5.
doi:10.1371/journal.pone.0040127.g001
Figure 2. si-HOXB5 inhibited the biological function of bladder cancer cells in vitro. A. Proliferation of bladder cancer cell lines T24, 5637
and TCCSUP. A CCK8 assay was used to examine cell growth of bladder cancer cells. B. Migration of bladder cancer cell lines. Left column, si-HOXB5
transfected group; right column, NC siRNA transfected group. All images are 610. Staining: purple, migration cells. C. Colony formation (C1) and
colony-forming efficiency (C2) of bladder cancer cells after transfection with si-HOXB5 or NC siRNA. Colony-forming efficiency = colonies/plated cells
6100%. *p,0.05, **p,0.01. NC, nonspecific control. MOCK, Lipofectamine only.
doi:10.1371/journal.pone.0040127.g002
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All data are expressed as the mean 6 SEM from at least three
separate experiments. The differences between groups were
analyzed using Student’s t test when only two groups were
compared, or, by one-way analysis of variance (ANOVA) when
more than two groups were compared. The age-adjusted odds
ratio (aOR) and 95% confidence interval (CI) for the relationship
between the HOXB5 39-UTR genotype frequencies and clinical
or histological features were determined by multivariate logistic
regression analysis using SPSS 17.0 with age considered as a factor.
All statistical tests were two-sided. Differences were considered
statistically significant at p,0.05.
Results
HOXB5 was Over-expressed in Human Bladder Cancer
Tissues and Cell Lines
RNA was extracted from 35 bladder cancer patients and 8
bladder cancer cell lines and the expression of HOXB5 was
measured using qPCR. As shown in Figure 1A, of 35 samples, 23
(,70%) exhibited higher expression of HOXB5 compared with
normal adjacent tissue (NAT). The expression of HOXB5 was also
higher in 6 of 8 bladder cancer cell lines (TCCSUP, 5637, T24,
RT4, HT-1376, and J82) than in normal bladder cells (Figure 1B).
Immunohistochemical studies using the HOXB5-specific antibody
confirmed that the expression of HOXB5 is higher in bladder
cancer tissues than normal bladder tissues (Figure 1C). However,
there was no correlation between the expression of HOXB5 and
the tumor grade or stage (data not shown). These results suggested
that the overexpression of HOXB5 may be common in some
bladder cancer tissues and in cell lines.
HOXB5 Promotes Cell Proliferation and Migration of
Bladder Cancer Cells
We found that HOXB5 was over-expressed in bladder cancer
tissues and in cell lines, indicating that HOXB5 may act as an
oncogene. To investigate the oncogenic function of HOXB5, we
transfected si-HOXB5 and NC siRNA into T24, 5637 and
TCCSUP cells. 48 hours after transfection, a CCK8 assay showed
that cell growth was significantly decreased in si-HOXB5
transfected groups compared with the NC group or mock group
(Lipofectamine only) (Figure 2A, p,0.05). We also found that the
migration ability of si-HOXB5 transfected cells was significantly
inhibited compared with the NC group or mock group (Figure 2B).
These results indicated that HOXB5 may promote cell pro-
liferation and the migration of bladder cancer cells, consistent with
a role of an oncogene.
Figure 3. HOXB5 is a target of miR-7. A. HOXB5 was predicted as a direct target of miR-7 by miRanda, PicTar and TargetScan. B. Luciferase
analysis in HEK-293T cells. WT, wild type. MUT, mutant type. C. Effect of miR-7 overexpression on the expression levels of endogenous HOXB5 in T24,
5637 and TCCSUP cells. Endogenous HOXB5 mRNA and protein levels were assayed by qPCR (C1) and Western blot (C2) respectively. b-actin, internal
control. **p,0.01, compared with NC transfectants. NC, nonspecific control.
doi:10.1371/journal.pone.0040127.g003
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To further explore the potential role of HOXB5 in tumorigen-
esis, we investigated the effect of HOXB5 on colony formation of
cancer cells in vitro. Three bladder cancer cell lines (T24, 5637 and
TCCSUP) were transfected with an si-HOXB5 or NC duplex, and
allowed to grow at very low density (500 cells for T24, 1,000 cells
for 5637 and TCCSUP) for about 14 days. Notably, si-HOXB5
inhibited, both in size and number, the ability of bladder cancer
cells to form colonies (Figure 2 C1). Further, the si-HOXB5
transfected cells showed lower colony-forming efficiency than the
NC-transfected cells (Figure 2 C2, p,0.01). These data further
supported the oncogenic effect of HOXB5 in bladder cancer cells.
SNP-1010A/G is Located within miRNA-7 Binding Site in
HOXB5 39-UTR
We found SNP rs9299 (1010 A/G) is located within the 39-UTR
of the HOXB5 gene using the NCBI SNP database. HOXB5 was
also predicted to be one of the target genes of miRNA-7 according
to 3 of the different systemic bioinformatics software that we used,
and the SNP (1010 A/G) was located within the miRNA-7 binding
site (Figure 3A).
To validate HOXB5 as a bona fide target of miR-7, a human
HOXB5 39-UTR fragment containing either the wild-type or
mutant miR-7-binding sequence was subcloned downstream of the
Renilla luciferase reporter gene as described in the Materials and
Methods section. The relative luciferase activity of the reporter
containing the wild-type HOXB5 39-UTR was significantly
suppressed when miR-7 was co-transfected (p,0.01). In contrast,
the luciferase activity of the reporter containing the mutant miR-7-
binding site was almost unaffected (p.0.05) (Figure 3B).
To further explore the regulation of HOXB5 expression by
miR-7, we transfected miR-7 mimics and NC into the cell lines
T24, 5637 and TCCSUP. After 48 hours, we examined the
HOXB5 mRNA and protein levels using qPCR and western blot.
We found that the HOXB5 mRNA and protein levels were down-
regulated in the miR-7 transfected groups compared with the NC
groups (Figure 3 C1 & C2).
These results indicated that miR-7 may regulate HOXB5
expression at both the post-transcription and mRNA levels.
SNP 1010A/G affects HOXB5 Expression
To investigate the affect of SNP 1010A/G on the expression of
HOXB5, we examined the mRNA levels of HOXB5 for the
1010A and 1010G alleles in the heterozygous GA genotype
bladder cancer tissues (13 cases) and cell lines (5637, RT4 and
J82), using the Taqman assay as described above. We found that
Figure 4. Expression of HOXB5 mRNA for each allele in heterozygous bladder cancer tissues and cell lines. A1. Expression of mRNA for
each allele in the heterozygous GA genotype cell lines (5637, RT4 and J82) and tissues (13 cases). A2. Expression of mRNA (Mean) for each allele in
heterozygous GA genotype cell lines and tissues. Y-axis, expression of HOXB5 mRNA. Ct: cycle threshold, calculated from Realtime-PCR machine. B1.
Expression of the heterozygous genomic DNA as an internal control. B2. Expression of the heterozygous genomic DNA (Mean) as an internal control.
Y-axis, expression in genomic DNA. ***p,0.001.
doi:10.1371/journal.pone.0040127.g004
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significantly higher than the mRNA with the 1010A allele in both
cancer tissues and cell lines (Figure 4A1 and A2). However, the
expression ratio of 1010G to 1010A in the genomic DNA from
these heterozygous cancer tissues and cell lines were similar
(Figure 4B1 and B2). These results showed that the 1010A/G SNP
in the HOXB5 39-UTR affected the expression of HOXB5
mRNA.
The Different Alleles Affect mRNA Stability and HOXB5
Expression Levels
To predict possible mechanisms how the 1010A/G SNP
results in differential HOXB5 expression levels, we used the
mRNA secondary structure prediction tool MFOLD to predict
the secondary structure of the mRNAs with the A and G alleles.
We found that the predicted minimal free energy (MFE) of the
secondary structure of the mRNA with the G allele was lower
than that of the mRNA with the A allele (25.4 vs 23.0). This
result indicated that the structure of the mRNA with the G allele
may be more stable than that for the mRNA with the A allele
(Figure 5A).
To further explore which allele (A or G) conferred more
stability, we measured the mRNA half-life because it has been
shown that the steady state of mRNA is closely related to the
mRNA half-life [21]. We examined the half-life of HOXB5
mRNA in the homozygous T24 and TCCSUP bladder cancer
cells (GG for T24 and AA for TCCSUP) after treatment with
actinomycin D, using qPCR. The results showed that the half-life
Figure 5. Different alleles affect HOXB5 mRNA stability and the activity of miR-7 binding. A. Secondary structures of HOXB5 mRNA
predicted by MFOLD. Minimal free energy (MFE) may reflect mRNA stability. B. Half-life of HOXB5 mRNA in T24 (GG genotype) and TCCSUP (AA
genotype) cells. The half-life for the mRNA with the G allele was about 11 hours, and about 3.7 hours with the A allele. C. HOXB5 expression level after
transfection with miR-7 relative to NC in 5637 cells (GA genotype). Both A and G alleles of the mRNA transfected with miR-7 exhibited down-
regulation relative to the NC group. The level of HOXB5 mRNA with the A allele decreased more than mRNA with the G allele. D. Luciferase analysis in
HEK-293T cells of miR-7 activity. Vector, psiCHECK-2 Vector. *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0040127.g005
Table 1. Genotype frequencies of the HOXB5 polymorphism in bladder cancer subgroups (G1 and G2–G3 groups).
HOXB5 1010A/G genotype G1 G2–G3 aOR
a (95%CI
b)p
N
c (%) N (%)
AA 51 (37.8%) 32 (12.5%) Ref
AG 68 (50.4%) 163 (63.7%) 3.82 (2.26–6.48) 0.001
GG 16 (11.9%) 61 (23.8%) 6.07 (2.99–12.31) 0.001
AG+GG (against AA) 84 (62.2%) 224 (87.5%) 4.25 (2.58–7.07) ,0.001
AG+AA (against GG) 119 (88.1%) 195 (76.2%) 0.40 (0.22–0.73) 0.003
aage-adjusted odds ratio,
b95% confidence interval,
cNumbers of people.
doi:10.1371/journal.pone.0040127.t001
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fold (11 h) than the mRNA half-life (3.4 h) in the cells with the
AA genotype (Figure 5B), indicating that the mRNA with the G
allele was more stable than the mRNA with the A allele. This
different stability on the two mRNAs may be the possible
mechanism that explains the different effect of the SNP on
HOXB5 expression.
The Binding Activity of miR-7 for Different Alleles of
mRNA affects HOXB5 Expression Level
We transfected miR-7 to a bladder cancer cell line (5637) with
the heterozygous GA genotype for 48 hours and measured the
HOXB5 mRNA level using the Taqman assay. We observed that
the overexpression of miR-7 could significantly inhibit the
expression level of HOXB5 mRNA compared with the NC
group? Interestingly, the expression level of the HOXB5 mRNA
with the A allele decreased much more than the level of the
mRNA with the G allele (Figure 5C), indicating that the binding of
miR-7 to the HOXB5 mRNA with the A allele was greater than
the mRNA with the G allele.
To validate our hypothesis, we carried out a luciferase assay.
The relative luciferase activity was suppressed much more in the
reporter containing the 1010A transfected with miR-7 than that
containing the 1010G allele (Figure 5D). These results showed that
the binding activity of miR-7 with either the 1010A or 1010G
allele may be another important mechanism involved in the
different HOXB5 expression levels affected by the SNP.
The Association between the 1010A/G HOXB5 Genotype
Frequency and Bladder Cancer
Next, we examined the association between 1010A/G HOXB5
genotype frequency and the clinical features of bladder cancer.
DNA was extracted from 391 patients with bladder cancer that
was confirmed by pathologists, and from 391 normal controls, and
the SNP (1010A/G) genotypes for each sample were analyzed. We
found that G allele (AG+GG) genotypes were associated with the
risk of high grade (Grade 2 and 3, aOR=4.25, p,0.001, Table 1)
and high stage (T2–T4, muscle invasive type, aOR=2.25,
p=0.003, Table 2) cancers as against low grade (Grade1) and
low stage (T1, non-muscle invasive type) cancers. We also showed
that the frequency of G genotypes (AG+GG) was higher in bladder
cancer group compared with the normal controls (aOR=1.48,
p=0.017) (Table 3).
Discussion
The HOX gene family has recently been identified as one of the
main factors in the normal development of the human organs. The
HOXB5 gene, which was found to be involved in lung and gut
development, was reported to be an important factor in human
disease, including cancers [14]. Here, we showed that the HOXB5
gene was frequently over-expressed in human bladder cancer
tissues and in cancer cell lines. In vitro experiments showed that
HOXB5 may act as an oncogene in human bladder cancer. We
found a SNP (1010 A/G) in the 39-UTR of the HOXB5 gene,
which was also within a miRNA-7 binding site. We observed that
this SNP could affect the expression of the HOXB5 gene.
Table 2. Genotype frequencies of the HOXB5 polymorphism in bladder cancer subgroups (Non-muscle invasive and Muscle-
invasive groups).
HOXB5 1010A/G genotype Non-muscle invasive Muscle-invasive aOR
a (95%CI
b)p
N
c (%) N (%)
AA 59 (26.8%) 24 (14%) Ref
AG 119 (54.1%) 112 (65.5%) 2.31 (1.35–3.47) 0.002
GG 42 (19.1%) 35 (20.5%) 2.05 (1.06–3.94) 0.031
AG+GG (against AA) 161 (73.2%) 147 (85.9%) 2.25 (1.33–3.79) 0.003
AG+AA (against GG) 178 (80.9%) 136 (79.5%) 0.91 (0.56–1.51) 0.917
aage-adjusted odds ratio,
b95% confidence interval,
cNumbers of people.
doi:10.1371/journal.pone.0040127.t002
Table 3. Genotype frequencies of the HOXB5 polymorphism in controls and bladder cancer groups.
HOXB5 1010A/G genotype Controls Bladder cancer aOR
a (95%CI
b)p
N
c (%) N (%)
AA 113 (28.6%) 83 (21.2%) Ref
AG 195 (50.4%) 231 (59.1%) 1.58 (1.12–2.22) 0.009
GG 83 (21%) 77 (19.7%) 1.263 (0.83–1.92) 0.276
AG+GG (against AA) 278 (71.4%) 308 (78.8%) 1.487 (1.07–2.06) 0.017
AG+AA (against GG) 308 (79%) 314 (80.3%) 0.922 (0.65–1.31) 0.646
aage-adjusted odds ratio,
b95% confidence interval,
cNumbers of people.
doi:10.1371/journal.pone.0040127.t003
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stability which can be affected by SNP may be involved in the
differential expression of HOXB5. Finally, the frequency of
1010G genotype was higher in bladder cancer group compared to
normal controls, and was related to the risk of high grade and high
stage bladder cancers.
Homeobox genes code for transcription factors that are
primarily involved in embryonic development. Several homeobox
gene families, including HOX, EMX, PAX, MSX and many
isolated divergent homeobox genes have been identified. The
HOX gene family is the one that has most often been found to
play a role in regulating network structure organization [22]. Over
10 years ago, the HOX genes were found to control embryonic
organ-specific patterning. During embryogenesis, these genes were
shown to code for transcription factors that regulate the expression
of subordinate genes [23]. The HOX gene family was also found
to be involved in human tumorigenesis [6,7,8,9]. Among HOX
gene family, HOXB5 gene has been found to play a role in the
patterning of airway branches during mouse lung morphogenesis
in Volpe et al’s study [10]. Later, they found HOXB5 gene was
also related to human lung morphogenesis and may play a role in
controlling airway patterning [19]. The HOXB5 gene was found
to related with vasculogenesis by its interaction with vascular
endothelial growth factor receptor-2 (VEGFR-2) and angiopoie-
tin-2 (Ang2) [24,25], indicating that HOXB5 may be involved in
tumorigenesis. Until now, the biological function of HOXB5 in
human bladder cancer has not been reported. In the present study,
we found that HOXB5 was over-expressed in human bladder
cancer and our in vitro experiment showed that HOXB5 may act as
an oncogene in bladder cancer.
In recent years, genome-wide association studies (GWAS) have
given us a deeper insight into the mechanisms related to genomic
changes in various cancers. Chang et al. identified several
susceptibility loci in human bladder cancer, including rs9642880
(nearest gene: MYC), rs710521 (nearest gene: TP63), and
rs2294008 (nearest gene: PSCA) among others [26].
The involvement of miRNAs in human cancer has been
discovered recently. In a previous study, we reported that
miRNA-143 and miRNA-125b act as tumor suppressors in human
bladder cancer by binding to the oncogenes RAS and E2F3
respectively [15,16]. 39-UTR polymorphisms in certain genes have
been reported to related with human disease, including hereditary
thrombophilia [27], urolithiasis [28], and increased sensitivity to 5-
fluorouracilchemotherapy[29].SNPsinmiRNA-bindingsiteshave
recently been discovered. Yu et al. conducted a genome-wide
analysis of SNPs located in the miRNA-binding sites of the 39-UTR
ofvarioushumangenesassociatedwithhumancancers.Theyfound
1,265 SNPs that were located within the miRNA-binding sites, and
suggested that these SNPs may affect expression of the miRNA
binding target [30]. Mishraet al. showed that SNP 829C/T located
withinthemiRNA-24bindingsiteofthe39-UTRoftheDHFRgene
led to overexpression of its target gene and resulted in resistance to
methotrexate [21]. In a previous study from our group, we reported
that the Mel-18 gene functioned as a tumor suppressor in prostate
cancer, and a SNP (1805A/G) in the miRNA-181a binding site
correlated with Mel-18 expression and clinical features in prostate
cancer [18].
Until now, no SNPs in miRNA-binding sites have been reported
in human bladder cancer. MiR-7 was shown to be down-regulated
in human glioblastoma and bladder cancer and a further study
showed that miR-7 may suppress tumor growth in human bladder
cancer by inhibiting growth factor receptor expression and by
impairing the antiapoptotic Akt-pathway [17]. Bioinformatics
analyses predicted a miR-7-binding SNP (1010A/G) within the 39-
UTR of the HOXB5 gene. Here, we reported a SNP (1010A/G)
that was located within the miR-7 binding site of the 39-UTR of
the HOXB5 gene, and found that the different SNP (A or G)
genotype could affect HOXB5 mRNA expression. Many 39-UTR
polymorphisms had been shown related with altered gene
expression, but the possible mechanisms were not fully understood
[21]. We propose that the SNP (1010A/G) may affect the
expression of HOXB5 in bladder cancer by differential mRNA
stability and binding activity of miR-7. Furthermore, multivariate
logistic regression analysis showed that genotypes with the G allele
(GG and AG) were associated with the risk of high grade (Grade 2
and 3, aOR=4.25, p,0.001) and high stage (T2–T4, muscle
invasive type, aOR=2.25, p=0.003) cancers. We also showed
that compared with normal controls, the genotypes with the G
allele were associated with the risk of bladder cancer (aOR=1.48,
p=0.017). These results suggested that the SNP located within the
miR-7 binding sites may affect HOXB5 expression, which in turn
may affect bladder tumorigenesis. In addition, this SNP may have
the potential to become a prognostic factor for bladder cancer.
miRNA binding site polymorphisms have only recently been
investigated. These polymorphisms may not only affect gene
expression, but could also have a relationship with clinical features
of cancer or even with the prognosis of cancer. In future studies,
we intend to source many more bladder cancer cases and use them
to carry out a longer-term study to discover whether or not this
SNP (rs9299) could be a good prognostic and prognosis factor for
bladder cancer.
In summary, in this study we showed for the first time that the
HOXB5 gene may act as an oncogene in human bladder cancer.
We found that a SNP (1010A/G) within the miR-7 binding site of
HOXB5 39-UTR affects HOXB5 expression and this SNP may be
correlated with bladder tumorigenesis and the risk of high grade
and high stage human bladder cancers. These results suggested
a possible mechanism for the effects of the miRNA binding site
polymorphism during bladder tumorigenesis and revealed a pos-
sible prognostic and prognosis factor for bladder cancer.
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